Journal of Medicinal Chemistry · 2023 · 42 citations · 22 references
PharmacyMedicinal ChemistryOncologyDrug DesignDrug DiscoveryMolecular OncologyLinker ChemistryRas Family OncogenesAnticancer ActivityAnticancer ChemotherapyChemical PropertiesDegradationKras InhibitorsKras-targeted TherapyTarget-ligand SelectivityTernary Complex Formation
The linker moiety of a proteolysis-targeting chimera (PROTAC) molecule plays a critical role in modulating the degradation activity, target selectivity, and physico-chemical properties. However, the basics and underlying mechanisms of chemical modifications of the linker structure causing dramatic changes in the PROTAC degradation activity warrant further investigation. Herein, we report the design and characterization of a highly potent and selective SOS1 PROTAC ZZ151. After systematically modifying the linker length and composition, we observed that subtle modification of just one atom of the linker moiety of ZZ151 resulted in remarkable changes in the formation of the ternary complex and thus dramatically affected the degradation activities. ZZ151 quickly, specifically, and effectively induced SOS1 degradation; displayed potent antiproliferation activities against a broad panel of KRAS mutant-driven cancer cells; and showed superior anticancer activities in the KRAS G12D - and G12V -mutant xenografts in mice. ZZ151 is a promising lead for developing new chemotherapies targeting KRAS mutants.
22
Universal sample preparation method for proteome analysis
Jacek R. Wiśniewski, Alexandre Zougman, Nagarjuna Nagaraj et al. · Nature Methods · 2009 · 8.7K citations
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd, Andrea Testa, Xavier Lucas et al. · Nature Chemical Biology · 2017 · 1.2K citations · Full text
Human Sos1: a Guanine Nucleotide Exchange Factor for Ras that Binds to GRB2
Pierre Teilhard de Chardin, Jacques Camonis, Nicholas W. Gale et al. · Science · 1993 · 800 citations